Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.
Stinne Ravn Greisen(Aarhus University), Bent Deleuran(Aarhus University), Kristian Stengaard‐Pedersen(Aarhus University Hospital), Holger Jon Møller(Aarhus University), Merete Lund Hetland(University of Copenhagen), Malene Hvid(Aarhus University), Anne Jørgensen(University of Copenhagen)
PubMed
November 1, 2011
Cited by 62
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders
|PEDIATRICS|2009|409
Chitosan/siRNA Nanoparticle–mediated TNF-α Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model
|Molecular Therapy|2008|298
Comparative Effectiveness of Injection Therapies in Lateral Epicondylitis
|The American Journal of Sports Medicine|2012|238
IL-25 in Atopic Dermatitis: A Possible Link between Inflammation and Skin Barrier Dysfunction?
|Journal of Investigative Dermatology|2010|214